{
    "clinical_study": {
        "@rank": "102318", 
        "arm_group": {
            "arm_group_label": "Stereotactic radiation", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and toxicity stereotactic body\n      radiation (SBRT) as consolidation following standard chemoradiation for patients with stage\n      III non-small cell lung cancer."
        }, 
        "brief_title": "Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Lung Cancer", 
        "condition_browse": {
            "mesh_term": "Lung Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This protocol will investigate the potential role of SBRT for patients with stage 3 NSCLC.\n      Eligible patients will first have received standard 50.4 Gy chemoradiation. Patients\n      entering the study will have the opportunity to receive SBRT as a noninvasive option as\n      compared to surgical resection. For patients who are not surgical candidates, SBRT after\n      50.4 Gy chemoradiation represents a technique of radiation consolidation that may be more\n      effective and less toxic than standard conventional fractionated radiation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PATIENT ELIGIBILITY Conditions for Patient Eligibility\n\n          -  Pathologically or cytologically confirmed NSCLC\n\n          -  Stage III NSCLC according to the AJCC 7th edition staging criteria. Stage II (T1-3N1)\n             patient that are deemed medically inoperable are also eligible.\n\n          -  Concurrent chemoradiation to a radiation dose of 50.4 Gy.\n\n          -  residual tumor volume after concurrent chemoradiation that is appropriate for SBRT:\n\n               -  Primary tumor <120cc (approximately 6cm diameter).\n\n               -  Mediastinal/Hilar disease: 1-2 involved regions <60cc (approximately\n                  5cmx3cmx3cm)\n\n          -  Absolute neutrophil count \u2265 1,000/uL, platelet \u2265 60,000/uL.\n\n          -  Total bilirubin \u2264 2x upper institutional limit of normal (ULN), and AST or ALT \u22645x\n             ULN.\n\n          -  ECOG performance status 0 to 2\n\n          -  Minimum life expectancy of 12 weeks.\n\n          -  Age older than 18 years.\n\n          -  Voluntary, signed written informed consent.\n\n          -  Women of childbearing potential must have a negative pregnancy test\n\n          -  Men and women of childbearing potential must be willing to consent to using effective\n             contraception while on treatment and for at least 1 months thereafter.\n\n        Conditions for Patient Ineligibility\n\n          -  Disease progression during or after standard chemoradiation to 50.4 Gy\n\n          -  Prior thoracic radiation other than the pre-operative radiation not greater than 50.4\n\n          -  Metastatic disease\n\n          -  Uncontrolled severe, intercurrent illness.\n\n          -  Women who are breast-feeding.\n\n          -  No chemotherapy within 2 weeks from the first SBRT treatment.\n\n          -  Concurrent anticancer therapy.\n\n          -  Prior complete resection of all NSCLC."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656460", 
            "org_study_id": "BrUOG 259"
        }, 
        "intervention": {
            "arm_group_label": "Stereotactic radiation", 
            "intervention_name": "stereotactic", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Lung Cancer", 
        "lastchanged_date": "April 2, 2013", 
        "location": [
            {
                "contact": {
                    "email": "patti_wingate@mhri.org", 
                    "last_name": "patti wingate", 
                    "phone": "401-729-2225"
                }, 
                "facility": {
                    "address": {
                        "city": "Pawtucket", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02860"
                    }, 
                    "name": "memorial Hospital of Rhode island"
                }, 
                "investigator": {
                    "last_name": "anthony thomas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kayla_rosati@brown.edu", 
                    "last_name": "kayla rosati", 
                    "phone": "401-863-3000"
                }, 
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02903"
                    }, 
                    "name": "Rhode Island Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "jaroslaw hepel, md", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "howard safran, md", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "thomas dipetrillo, md", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer", 
        "overall_contact": {
            "email": "kayla_rosati@brown.edu", 
            "last_name": "Kayla Rosati", 
            "phone": "401-863-3000"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Any toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0", 
            "measure": "early and intermediate toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656460"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brown University", 
            "investigator_full_name": "Dr Thomas DiPetrillo", 
            "investigator_title": "Prinicipal Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Brown University", 
        "sponsors": {
            "collaborator": {
                "agency": "Memorial Hospital of Rhode Island", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Dr Thomas DiPetrillo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}